Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

This review discusses neutrophil-associated and infiltrative scarring alopecias, as well as promising new treatments, but reports no new clinical results.

This review highlights that while dexamethasone may reduce mortality in severe COVID-19, no other drugs have proven effectiveness for treatment, emphasizing the need for clinical trials of existing medications.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

This review examines menopause's endocrinology, treatment history, and associated changes, noting key issues for midwife management but reports no new clinical results.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.

This article discusses diagnostic and treatment options for excessive hair growth in women, noting a need for holistic approaches to address associated psychological issues, but it does not present new clinical findings.

This review discusses recent advancements in female contraception and covers topics like adapted regimens, non-invasive sterilization, and the promise of new methods, but it reports no new clinical findings.

This article reviews the limited evidence on testosterone therapy for premenopausal women and notes a lack of long-term safety and effectiveness data for this population.

The document concludes that managing PCOS involves treating symptoms and reducing long-term metabolic risks, with lifestyle changes being important.

This source suggests that migraine prevalence increases in transgender women using oestrogen and decreases in transgender men using testosterone, with high oral oestrogen doses in transgender women potentially linked to aura risk.

This article discusses the various roles of steroids in vertebrate organ systems and notes several glucocorticoids that were among the Top 200 Drugs by sales in the 2010s, but it reports no new clinical findings.

This review discusses recent advances in hair follicle research, highlighting therapeutic and cosmetic applications, but reports no new study results.

Testosterone therapy can improve sexual function in women but long-term safety is unclear.

This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.

This study reports that hair samples can be used to track chronic hormone levels, revealing stress, reproductive, and sodium regulation patterns in wildebeest related to environmental factors.

This article reviews the complications and health risks associated with polycystic ovary syndrome and reports no new clinical findings.

The document concludes that managing skin conditions during pregnancy is important and requires specialized care.

In this study, polycystic ovary syndrome was the most prevalent cause of androgen excess, and suppressive hormonal therapy improved hirsutism, menstrual dysfunction, and acne in most patients, though side effects were common.

This review discusses the current understanding of polycystic ovary syndrome, focusing on its epidemiology, pathophysiology, diagnosis, management, and future research directions, but reports no new clinical results.

This review discusses the various phenotypes and diagnostic challenges of polycystic ovary syndrome, highlighting its complex pathophysiology and associated health risks, and reports no new clinical results.

This study found that the ovarian stromal area to total ovarian area ratio alone is not a strong predictor of biochemical hyperandrogenism in Thai women with PCOS, but combining it with clinical hyperandrogenism improves prediction.

This abstract discusses the challenges of diagnosing and managing PCOS, highlighting that individualized management, lifestyle modifications, and medical treatments such as contraceptives and metformin are recommended to address hormonal imbalances and co-morbidities.

This review discusses the definition of polycystic ovary syndrome proposed by the AE-PCOS Society Task Force, emphasizing hyperandrogenism, ovarian dysfunction, and excluding related disorders, while noting potential variations needing more research.

This study estimates the total cost of evaluating and treating polycystic ovary syndrome in reproductive-aged women in the United States to be $4.36 billion, suggesting more liberal screening could be beneficial.

This review discusses the neurobiology of sexual function and reports no new results; the authors cover multiple endocrine and neurotransmitter influences on sexual desire, arousal, and orgasm stages.

This review discusses the epidemiology, causes, diagnosis, and management of hirsutism in women, noting that effective treatment requires addressing the root cause as well as the hair growth.

This review discusses the various evidence-based and potential applications of metformin in treating and preventing symptoms and complications associated with polycystic ovary syndrome but reports no new clinical results.

This review discusses the roles of androgens and estrogens in skin functions and disorders, and highlights the use of estrogen-progestin treatments and anti-androgens in managing hirsutism and acne, without reporting new results.

This review discusses the role of hormones in acne vulgaris and highlights the need for further research on their mechanisms of action; it reports no new clinical results.